Price(1)(2)Amount ofRegistration FeeCommon Stock, par value $0.0001 per share$172,500,000$22,218(1)Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.(2)Includes the aggregate offering price of additional shares that the underwriters have the option to purchase.The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
We will not receive any proceeds from the sale of shares by the selling stockholders.Our common stock is listed on The NASDAQ Global Select Market under the symbol “FMI.” As of March 19, 2014, the last reported sale price
, 2014Table of ContentsTABLE OF CONTENTSPageProspectus Summary1Risk Factors11Special Note Regarding Forward-looking Statements13Use of Proceeds15Dividend Policy16Market Price of Common Stock17Capitalization18Management20Executive Compensation28Certain Relationships and Related Party Transactions40Principal and Selling Stockholders43Description of Capital Stock45Shares Eligible for Future Sale50Certain Material U.S. Federal Income Tax Considerations52Underwriting58Legal Matters63Experts63Where You Can Find More Information63Incorporation of Documents by Reference64We have not authorized anyone to provide you with any information or to make any representation, other than those contained in this prospectus, any
Reference.” Our historical results are not necessarily indicative of our future results.Year Ended December 31,201320122011(in thousands, except share andper share data)Consolidated Statement of Operations Data:Revenue$28,990$10,645$2,057Costs and expensesCost of revenue11,6595,681258Selling and marketing12,3263,4541,555General and administrative21,8658,6446,992Research and development24,90114,7779,023Total costs and expenses70,75132,55617,828Loss from operations(41,761)(21,911)(15,771)Interest expense, net(235)(421)(421)Other expense, net(948)(61)(845)Net loss(42,944)(22,393)(17,037)Accretion of convertible preferred stock(139)(286)(296)Net loss applicable to common stockholders$(43,083)$(22,679)$(17,333)Net loss per common share applicable to common stockholders, basic and diluted$(4.64)$(10.47)$(14.06)Weighted average common shares outstanding, basic and diluted9,294,7302,166,8321,232,658As of December 31, 2013ActualPro Forma(1)(2)(in thousands)Consolidated Balance Sheet Data:Cash and cash equivalents$124,293$Working capital117,551Total assets157,268Accumulated deficit(89,763)Total stockholders’ equity$131,711$(1)Pro forma to reflect the sale by us of shares of our common stock offered in this offering, at the assumed public offering price of
90 days after the date of this prospectus pursuant to lock-up agreements that our officers, directors, stockholders selling shares in this offering, and certain other stockholders have signed, as more fully described in the section entitled
These amounts do not correspond to the actual value that will be recognized by the named executive officers.(2)The bonuses for the year ended December 31, 2013 have not yet been determined, but are expected to be approved by our compensation committee in April 2014.(3)Pursuant to the terms of his employment agreement, Dr. Pellini is entitled to living expense assistance in connection with his commuting to our principal executive offices
following a change of control, by the officer for good reason, provided that he executes, not revokes and fully complies with a separation agreement that includes a general release of us and our affiliates.30Table of ContentsIn addition to the previously described severance provisions, pursuant to the terms of his employment
Table—2013Director nameFees earned orpaid in cash($)(1)Option awards($)(2)All othercompensation($)Total($)Alexis Borisy$25,333——$25,333Brook Byers12,000——12,000Mark Levin12,000——12,000Evan Jones30,833$70,300—101,133David Schenkein, M.D.40,25038,306—78,566Krishna Yeshwant, M.D.12,667——12,667(1)Includes amounts paid pursuant to our non-employee director compensation policy described below, which was implemented as of our initial public offering.
of directors will be eligible for an option grant to purchase up to 22,445 shares of our common stock under our 2013 Plan on the date he or she first becomes a non-employee director, which will vest in two equal annual installments during the two
Approval by our stockholders of amendments to the 2010 Plan must be obtained if required by law.35Table of ContentsAs of March 15, 2014, options to purchase 2,497,644 shares of common stock and
entered into a securities purchase agreement pursuant to which we issued an aggregate of 10,250,000 shares of our Series A Preferred Stock at a price of $1.00 per share to certain investors.The following table summarizes the participation in the Series A Preferred Stock financing by any of our directors, executive officers, holders of
transactions with directors, officers and holders of 5% or more of our voting securities and their affiliates, or each, a related party, must be approved by our audit committee or another independent body of our board of directors.42Table of ContentsPRINCIPAL AND SELLING STOCKHOLDERSThe following table and footnotes set forth certain information known to us regarding beneficial ownership of our capital stock as of
by such trusts.(13)Includes options to purchase 349,150 shares exercisable within 60 days of March 15, 2014.(14)Selling stockholder information to be provided by filing of an amendment to the registration statement of which this prospectus forms a part.44Table of ContentsDESCRIPTION OF CAPITAL STOCKThe following descriptions are summaries of the material terms of our amended and restated certificate of incorporation and amended and restated
Capital Stock—Registration Rights” for additional information.Stock Option PlansIn September 2013 and March 2014 we filed effective registration statements on Form S-8 under the Securities Act to register our shares issued